Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors Journal Article
| Authors: | Chong, C. R.; Park, V. J.; Cohen, B.; Postow, M. A.; Wolchok, J. D.; Kamboj, M. |
| Article Title: | Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors |
| Abstract: | Background. Cancer patients are at a higher risk for developing influenza (flu)- related complications. It is unclear if the flu vaccine exacerbates immune events in patients treated with immune checkpoint inhibitors (ICIs). Methods. We conducted an institutional review board-IRB-approved retrospective review of advanced cancer patients on ICIs who received the flu vaccine during three 3 consecutive seasons: 2014-2015, 2015-2016, and 2016-2017. The primary outcome assessed was any "new onset" immune-related adverse event (IRAE). A subset analysis of vaccinated patients newly treated with anti-programmed cell death protein 1 (PD-1) agents (nivolumab or pembrolizumab) was conducted to assess overall IRAE rates for comparison with published clinical trials. Results. During the three 3 seasons, 370 patients met criteria for ICI and vaccination within similar to twoapproximately 2 months (65 days). The most common underlying cancers were lung (46%) and melanoma (19%); 61% of patients received an anti-PD-1 agent only. In the entire cohort, 20% experienced an IRAE (any grade); incidence of grade 3 or 4 toxicity was 8%. No grade 5 events occurred. In the subset of 170 patients newly treated with anti-PD-1 agents, the overall IRAE rate was 18% and, grade 3/4 events occurred in 7.6%. Influenza was diagnosed in 2 patients. Conclusions. No increase in incidence or severity of IRAEs was detected in patients on ICIs who received the inactivated influenza vaccine within similar to approximately 2 months of ICI. For newly treated patients on anti-PDI-1 agents, IRAE rates were comparable to those from published clinical trials and did not vary with order of administration. Routine seasonal flu vaccination is encouraged in patients on ICIs. |
| Keywords: | chemotherapy; ipilimumab; safety; influenza vaccine; infections; immune checkpoint inhibitors |
| Journal Title: | Clinical Infectious Diseases |
| Volume: | 70 |
| Issue: | 2 |
| ISSN: | 1058-4838 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-01-15 |
| Start Page: | 193 |
| End Page: | 199 |
| Language: | English |
| ACCESSION: | WOS:000506801400004 |
| DOI: | 10.1093/cid/ciz202 |
| PROVIDER: | wos |
| PMCID: | PMC6938975 |
| PUBMED: | 30874791 |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work